

Join IQVIA at Virtual ISPOR Europe 2020

Real world evidence. Real HEOR and market access expertise. Real results.

IQVIA's real world evidence experts will be contributing to a range of events at Virtual ISPOR Europe 2020, **16–19 November**.

Discover the latest insights from our on-demand presentations, live spotlight session and more than 70 poster abstracts, seven of which have qualified for the ISPOR Gold Certificate of Recognition as a Top 10% poster.



Oral presentations

CL4 • Concerns, quality of life, access to care and productivity of the general population during the first 8 weeks of the coronavirus lockdown in Belgium and the Netherlands

Michels R, Goossens LMA, Bruin R, van Ballegooijen H, Krol M

[View](#)  On demand now



On-demand webinar

Expanding COA in 2020: Guidance in RWE and improving communication between different stakeholders

Moderator:

Katja Rudell, Parexel Access Consulting, Parexel International, Chittering, UK

Speakers:

Lynda Doward, RTI Health Solutions, Didsbury, UK

Bryan Bennett, Bristol Myers Squibb (BMS), Uxbridge, Middlesex, UK

Angela J Jane Rylands, Kyowa Kirin International plc, UK, Marlow, BKM, UK

Ana Maria Rodriguez, IQVIA Madrid, Spain

[View](#)  On demand now



Spotlight session

SP2 • Is credible, robust real-world evidence just a myth?

[Access](#)  Live event

Tuesday, 17 November • 17:00–18:00 CET

Moderator:

Anja Schiel, Norwegian Medicines Agency, Oslo, Norway

Speakers:

Nancy Dreyer, IQVIA, Cambridge, MA, USA

Xavier Kurz, European Medicines Agency, Amsterdam, Netherlands

Robert Golub, JAMA, Chicago, IL, USA



These virtual activities are available on demand.

[Click here](#) to access.

Virtual ISPOR Europe 2020

16-19 November 2020
#ISPOREurope

Improving Health: Establishing Incentives and Sharing Values



Poster abstracts

GENERATING THE RIGHT EVIDENCE

Explore in our poster abstracts at Virtual ISPOR Europe how we are applying rigorous, innovative approaches to seamlessly integrate unparalleled data assets and best-in-class technology-enabled analytics to deliver representative, relevant results of benefits, risks and outcomes across a range of therapy areas.

CODE	BIOLOGICS/BIOSIMILARS/REGENERATIVE MEDICINE (PBI)	AUTHORS
PBI12	BUDGET IMPACT ANALYSIS OF BARICITINIB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA	Almodaimagh H, Alrumaih A, Alabdulkarim HAA, Alsaqa'aby M, Alturaiki A, Erdogan A, Alhowimel M, Alhammad A, El Ojeil R, Biswas C
PBI13	BUDGET IMPACT ANALYSIS TO ASSESS THE IMPACT OF ADALIMUMAB-ATTO (BIOSIMILAR) COMPARED TO ADALIMUMAB IN AUTOIMMUNE DISEASES IN UNITED ARAB EMIRATES	Farghally M, Sara Ahmad MA, Sharma Y, Shamekh M, Mohamed O
PBI14	BUDGET IMPACT ANALYSIS OF A REDUCED MAINTENANCE DOSE OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IN THE UNITED KINGDOM	Kiri S, Arteaga Duarte C, Lyris N, Lamotte M, Gerlier L
PBI15	THE ECONOMIC BURDEN FOR THE MANAGEMENT OF MODERATE-TO-SEVERE PSORIASIS IN THE KINGDOM OF SAUDI ARABIA	Al-Omar H, Altawil E, R. Hamadah I, Alsaqa'aby M, Al Shahwan MA, Al-Haddab MA, et al
PBI57	EFFECTIVENESS OF BIOLOGIC TREATMENTS FOR PSORIATIC ARTHRITIS IN ITALY – PRELIMINARY RESULTS OF THE CHRONOS STUDY	Colombo D, Simoni L, Ori A, Flocchi M, Frassi M, Pagano Mariano G, et al
PBI58	PERSISTENCE OF TREATMENT WITH BIOLOGICS FOR PATIENTS WITH PSORIASIS – AN ANALYSIS OF A FRENCH PRESCRIPTION DATABASE	Kemula M, Morand F, De Nascimento J, Sohr A
CODE	CANCER (PCN)	AUTHORS
PCN60	COST-EFFECTIVENESS ANALYSIS OF IXAZOMIB PLUS LENALIDOMIDE-DEXAMETHASONE VERSUS DARATUMUMAB PLUS LENALIDOMIDE-DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS WHO RECEIVED MORE THAN ONE PRIOR TREATMENT IN CHINA	Zhao X, Feng Y, Zhu L, Liu J
PCN62	A RETROSPECTIVE COHORT STUDY OF THE NATIONAL HEALTHCARE RESOURCE UTILISATION (HCRU) AND COSTS OF TREATING MULTIPLE MYELOMA (MM) IN FRANCE USING THE SYSTÈME NATIONAL DES DONNÉES DE SANTÉ (SNDS) DATABASE	Bessou A, Colin X, De Nascimento J, Sopwith W, Ferrante SA, Gorsh B, Gutierrez B, Sansbury L, Willson J, Sapra S, Wang F
PCN91	MULTIPLE MYELOMA IN PORTUGAL – BURDEN OF DISEASE AND COST OF ILLNESS	Neves M, Trigo F, Bergantim R, João C, Lúcio P, Mendes J, Neves M, Pedrosa H, Galdes C
PCN102	USING A BUDGET IMPACT MODEL (BIM) AS A DECISION-MAKING TOOL AT THE HOSPITAL LEVEL IN FRANCE – AN EXAMPLE OF CPX-351 IN PATIENTS WITH NEWLY DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)	Monnier R, Bourguignon S, Guindeuil G, Pawlak M
PCN190	KADOR - A FRENCH RETROSPECTIVE STUDY DESCRIBING THE THERAPEUTIC MANAGEMENT OF PATIENTS WHO RECEIVED TRASTUZUMAB BASED NEOADJUVANT TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER (EBC)	Cottu P, Tredan O, Livartowski A, Perol D, Gilbert M, Ghorbal R, Dupin J, Maillard C
PCN192	HOSPITALIZATIONS AND OUTPATIENT VISITS (H&OV) IN MODERATE AND SEVERE ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) PATIENTS IN FINLAND AND SWEDEN	Itälä-Remes M, Viayna E, Niklasson M, Keränen M, Thunström D, Pfeiffer M, Roset M, Lara N, Sabatelli L
PCN243	PRICE CHANGES AFTER INDICATION EXTENSION IN THE GERMAN EARLY BENEFIT ASSESSMENT	Freiberg M, Karimi M, Böckmann D, Wagner P
PCN274	COMPARING DIFFERENT MACHINE LEARNING ALGORITHMS IN PYTHON AND USING BEST FIT MODEL FOR BREAST CANCER PREDICTION	Mittal R, Goyal R
PCN287	AN INNOVATIVE METHODOLOGY TO PREDICT THE SIZE OF TREATMENT TARGETED POPULATION COMBINING DATA FROM A RETROSPECTIVE REGISTRY (KADOR) AND A HOSPITALIZATION DATABASE	Perol D, Cottu P, Tredan O, Livartowski A, Gilbert M, Ghorbal R, Dupin J, Maillard C
PCN299	UNDERSTANDING THE PATIENT EXPERIENCE OF BILIARY TRACT CANCER – A QUALITATIVE PATIENT INTERVIEW STUDY	Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, Melisi D, Macarulla T, Ueno M, Meyers O, Workman C, Bachini M, Cohen G
PCN321	PRO CONCEPTUAL MODELS IN LUNG CANCER – THE VALUE OF MULTIPLE DATA SOURCES	Meyers O, Reaney M
CODE	CARDIOVASCULAR DISORDERS (PCV)	AUTHORS
PCV56	COST-EFFECTIVENESS ANALYSIS OF APIXABAN IN ATRIAL FIBRILLATION INDICATION – IRAQ (PRIVATE SECTOR)	Al-Saffar H, Al-Zaidy M, Mohammed S, Al Yassin A, Haji G, Alghadhbani M, Shelbaia M, Basu S, Mohamed O

[Click here](#) for further details of poster abstracts available on the Virtual ISPOR Europe 2020 website

CODE	DIABETES/ENDOCRINE/METABOLIC DISORDERS (PDB)	AUTHORS
PDB1	TYPE 1 DIABETES IS ASSOCIATED WITH URINARY SYSTEM AND GENITAL TRACT DISORDERS IN WOMEN	Kostev K, Dombrowski S, van den Boom L
PDB8	NETWORK META-ANALYSIS FOR COMPARATIVE EFFICACY AND SAFETY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTORS IN DIABETIC MACULAR OEDEMA	Kochar P, Randhawa S, Rajpal S, Aggarwal A, Goyal R, Soni P, Evanka C
PDB16	THE COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN TYPE 2 DIABETES IN DENMARK, INCORPORATING CARDIOVASCULAR OUTCOMES	Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary EC, Ejksjaer N
PDB62	PROFILE OF PATIENTS TREATED WITH INSULIN LISPRO 200 U/ML IN THE REAL WORLD – PROFILE IL-200 STUDY	Rubio M, Artime E, Duque N, Spaepen E, Carreño Á, Díaz Cerezo S
PDB64	USE OF MOBILE HEALTH INTERVENTION FOR THE SELF-MANAGEMENT IN PATIENTS WITH DIABETES MELLITUS – A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS	Adil M, Fischer T, Schmalhofer C, Bonduelle D
PDB69	DOES INCLUDING EGFR ALONG TO HBA1C AS A DRIVER OF TREATMENT SWITCH CHANGE OUTCOMES IN COST-EFFECTIVENESS ANALYSES IN TYPE 2 DIABETES?	Ramos M, Lamotte M
PDB85	DISPENSED INSULIN DOSE BEFORE AND AFTER SODIUM-GLUCOSE TRANSPORT PROTEIN 2 INHIBITOR INITIATION IN DIABETES MELLITUS TYPE 2 PATIENTS IN NETHERLANDS – A RETROSPECTIVE DATABASE STUDY	Cai R, Peters ML, Wammes K, Chevalier P, Schram R, He K, Krol M, Hoekstra J
CODE	DRUGS & GENERICS (PDG)	AUTHORS
PDG3	MANAGEMENT OF METASTATIC BREAST CANCER IN REAL-WORLD CLINICAL PRACTICE – RELEVANCE OF TARGETED THERAPY WITH TREATMENT OUTCOMES	Cadavid A, Casado D, Ricote I, Merino-Montero S, González M
CODE	GASTROINTESTINAL DISORDERS (PGI)	AUTHORS
PGI6	BURDEN OF DISEASE AND COST OF ILLNESS OF INFLAMMATORY BOWEL DISEASE IN PORTUGAL	Magro F, Portela F, Lago P, Chagas C, Moreira F, Pereira F, Rodrigues B, Pedrosa H, Correia L
PGI12	HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN FIVE EUROPEAN COUNTRIES – THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW	Ferrante M, Siproudhis L, Poggioli G, Reinshagen M, Milicevic S, Roset M, Bent-Ennakhl N, D'Ambrosio R, Fernández A, Panes J
PGI14	COSTS RELATED TO PLATELETS TRANSFUSION IN ITALY IN PATIENTS WITH THROMBOCYTOPENIA	Tucci C, Lombardi G, Fiorentino F, Teruzzi C, Colombo A, Cioni L, Urbinati D
PGI21	NO ASSOCIATION BETWEEN THE NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND DEMENTIA	Labenz C, Zingel R, Kostev K, Schattenberg JM
PGI28	MULTI-DIMENSIONAL SCALING (MDS) AND CORRESPONDENCE ANALYSIS (CA) AS QUANTITATIVE METHODS FOR PATIENT-REPORTED OUTCOME (PRO) DEVELOPMENT	Flore G, Rohay J, Ho C
CODE	INFECTIOUS DISEASES (PIN)	AUTHORS
PIN25	COST-EFFECTIVENESS OF VABOREM FOR THE TREATMENT OF CRE-KPC INFECTIONS IN ITALY	Fiorentino F, La Malfa P, Gori M, Vlachaki I, Urbinati D
PIN32	COST-EFFECTIVENESS OF THE CELL-BASED QUADRIVALENT VERSUS THE STANDARD EGG-BASED QUADRIVALENT INFLUENZA VACCINE IN GERMANY. RESULTS OF A DYNAMIC TRANSMISSION MODELLING APPROACH	Cai R, Eichner M, Schwehm M, Rajaram S, Mould-Quevedo J, Lamotte M
PIN72	BURDEN OF INFLUENZA-RELATED AND ASSOCIATED HOSPITALIZATIONS IN FRANCE FROM SEASON 2010/11 TO 2017/18	Lemaitre M, Fouad F, Carrat F, Crépey P, Gaillat J, Gavazzi G, Launay O, Mosnier A, Levant MC, Uhart M
PIN75	CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN THE US – A DESCRIPTIVE CLAIMS-BASED STUDY FROM A NATIONAL PERSPECTIVE	Divino V, Wang Y, Beggs C, DeKoven M
PIN78	COUNTY-LEVEL DIFFERENCES IN COVID-19 CASES AND FATALITIES IN GERMANY	Batscheider A, Gossmann JA, Greiner RA, Shlaen E, Antoni B, Böckmann D, Mittal R, Böhm D
PIN121	LONGITUDINAL TRENDS AND BURDEN OF TROPICAL INFECTIOUS DISEASES IN COLOMBIA – A REAL-WORLD DATA ANALYSIS	Hernández F, Julian G
PIN167	PATIENT-REPORTED OUTCOMES TO CAPTURE THE SIGNS, SYMPTOMS AND IMPACTS OF COVID-19 AND THE IMPACT OF THE PANDEMIC ON PEOPLE WITH AND WITHOUT INFECTION	Reaney M, Heuer K, Turnbull J, Paty J

WINNER OF AN ISPOR GOLD CERTIFICATE OF RECOGNITION AS A TOP 10% POSTER



[Click here](#) for further details of poster abstracts available on the Virtual ISPOR Europe 2020 website

CODE	MENTAL HEALTH (PMH)	AUTHORS
PMH7	WEIGHT CHANGE IN SCHIZOPHRENIC PATIENTS PRESCRIBED WITH ANTIPSYCHOTICS IN UNITED STATES – A REAL-WORLD EVIDENCE STUDY	Pochiero I, Calisti F, Comandini A, Del Vecchio A, Costamagna I, Rosignoli MT, Heiman F, Peduto I, Cattaneo A
PMH13	HEALTHCARE RESOURCES UTILIZATION AND SICK LEAVE EXPERIENCE OF MAJOR DEPRESSIVE DISORDER PATIENTS INITIATING TREATMENT WITH ANTIDEPRESSANTS IN GERMANY AND SPAIN	Bonelli A, Cattaneo A, Comandini A, Di Dato G, Puricelli F, Heiman F, Pegoraro V, Palao D, Roca M, Volz HP, Kasper S
PMH27	BURN INJURY IS ASSOCIATED WITH THE INCIDENCE OF PSYCHIATRIC DISORDERS IN GERMAN PRIMARY CARE PATIENTS	Bich CS, Dombrowski S, Kostev K, Baus A, Jacob L
PMH33	THE USE OF HIGH-DOSE STATIN IS ASSOCIATED WITH A REDUCED RISK OF ALL-CAUSE DEMENTIA	Kostev K, Zingel R
CODE	MULTIPLE DISEASES (PMU)	AUTHORS
PMU24	PHYSICAL AND PSYCHICAL DISORDERS ASSOCIATED WITH HOSPITAL ADMISSIONS IN GERMANY	Kostev K, Dombrowski S, Stapf M
PMU58	RETROSPECTIVE ANALYSIS OF THE METHODOLOGICAL LIMITS ON BUDGET IMPACT MODEL CARRIED OUT IN THE FRAMEWORK OF THE SUBMISSION OF A HEALTH ECONOMIC EVALUATION DOSSIER TO THE CEESP	Duhamel J, Kandel M, Maurel F
PMU110	DETECTING INCREASING COSTS ASSOCIATED WITH HEALTH BENEFITS IN URUGUAY – A HEALTH CLAIMS DATA ANALYSIS	Hernández F, Julian G
CODE	NEUROLOGICAL DISORDERS (PND)	AUTHORS
PND4	A NETWORK META-ANALYSIS COMPARING CLINICAL SAFETY AND TOLERABILITY OF ECULIZUMAB AND INEBILIZUMAB FOR THE TREATMENT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER	Soni P, Evanka C, Randhawa S, Kochar P, Rajpal S, Goyal R
PND11	INDIRECT TREATMENT COMPARISON OF INEBILIZUMAB VERSUS ECULIZUMAB FOR SAFETY AND TOLERABILITY IN NEUROMYELITIS OPTICA SPECTRUM DISORDER	Soni P, Evanka C, Kochar P, Randhawa S, Rajpal S, Goyal R
PND54	HEALTHCARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF MIGRAINE IN THE UNITED KINGDOM, FRANCE, AND SPAIN – RESULTS OF A REAL-WORLD STUDY	Irimia P, Benhaddi H, Morand F, Maurel F, Lanteri-Minet M, Thompson S, Goadsby PJ
CODE	NO SPECIFIC DISEASE (PNS)	AUTHORS
PNS7	A METHODOLOGICAL APPROACH FOR EVIDENCE GENERATION – DESIGNING AN ENRICHED OBSERVATIONAL STUDY IN ITALY	Andreis D, Cipelli R, Ori A, Fiori G, Heiman F, Urbinati D, Simoni L
PNS16	REAL PURCHASING PRICE NEGOTIATED WITH THE ITALIAN MEDICINE AGENCY IN 2016-2018	Urbinati D, Tettamanti A, Rova A
PNS37	ECONOMIC ANALYSIS FOR EARLY INTRODUCTION OF AMINO ACID FORMULA FOR COW'S MILK PROTEIN ALLERGY IN THE GCC COUNTRIES	Miqdady M, Tzivinikos C, Siddiqui A, Al Mutaury S, Al-Ahmedi N, Alsawi N, et al
PNS56	EXTRA BUDGETARY PAYMENTS FOR NEW EXAMINATION AND TREATMENT METHODS (NUB) – TRENDS FROM 2016 TO 2020 AND POTENTIAL FACTORS FOR SUCCESS OR FAILURE	Kuschel AS, Schuh I, Dose J, Drews J, Bonduelle D, Kaul T, Pirner C
PNS93	A COMPARISON OF ITALIAN AND ENGLISH GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES	Fiorentino F, Fattore C, Lombardi G, Urbinati D
PNS149	HTA RESHAPING – RETHINKING THE HEALTH TECHNOLOGY ASSESSMENT FRAMEWORK IN PORTUGAL – FINAL RESULTS	Alves J, Barata B, Rodrigues B, Caetano R, Cruz PB, Sousa J, Pereira J
PNS203	MACHINE LEARNING FOR SUBPOPULATION ANALYSIS IN DATASETS WITHOUT CONTROL ARM	Wang Y, Wei G, Wang Y, Behnke M, Reiner E, Chaudhuri K, Reeve R, McKemey A, Oliva C, Reynolds M
PNS207	PATIENT AND SUB-POPULATION SIMULATION VIA MULTIDIMENSIONAL CORRELATION GENERATION (MCG) AND WEIGHTED K NEAREST NEIGHBORS (KNN) ALGORITHMS FOR CLINICAL TRIALS AND REAL-WORLD DATA	Wei G, Wang Y, Wang Y, Behnke M, Reiner E, Chaudhuri K, Reeve R, McKemey A, Oliva C, Kelly B
PNS238	IS THERE A NEED FOR A CONSENSUS ON HOW TO SYNTHESIZE A SINGLE MEANINGFUL WITHIN-PATIENT CHANGE THRESHOLD FROM DIFFERENT SOURCES?	Ivanescu C, Niklasson A, Ryden A, Gwaltney C, New M, Casamayor M, Reaney M
PNS250	HOW TO DEAL WITH COVID-19-RELATED INTERCURRENT EVENTS ON TRIAL ESTIMANDS FOR PATIENT-REPORTED OUTCOMES (PRO) OBJECTIVES	Skaltsa K, Ivanescu C, Reaney M

WINNER OF AN ISPOR GOLD CERTIFICATE OF RECOGNITION AS A TOP 10% POSTER



[Click here](#) for further details of poster abstracts available on the Virtual ISPOR Europe 2020 website

CODE	RARE & ORPHAN DISEASES (PRO)	AUTHORS
PRO63	CUTANEOUS T-CELL LYMPHOMA – PATIENT’S PERCEPTION AND CHALLENGES	Upadhayay C, Kumar J, Goyal R
PRO76	PULMONARY ARTERIAL HYPERTENSION IN BRAZIL – TREATMENT PATTERNS AND HOSPITALIZATION BASED ON PRIMARY RESEARCH 	Souza PVS, Nacazume J, Lima PVP, Watanabe SF, Laranjeira FO, Menezes LP, Morais AD
PRO102	REIMBURSEMENT DECISION DRIVERS OF CAR T-CELL THERAPIES ACROSS THE EU-5, CANADA AND THE US – AN INSIGHT INTO PATIENT ACCESS	Ghosh S, Paul T, Chatterjee M
PRO126	PATIENT SUPPORT IN ORPHAN INDICATION – PERSISTENCE AND SUPPORT	Freiberg M, Booker A, Lukas M, Thiele J
PRO141	TREATMENT PATTERNS PRIOR TO THE USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN GERMANY 	Schill M, Taieb V, Richter H, Lebioda A
CODE	RESPIRATORY-RELATED DISORDERS (PRS)	AUTHORS
PRS11	HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD) AND SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE IN FRANCE	Nasser M, Rabiéga P, Boussel L, Si-Mohamed S, Barbet V, Marque S, Massol J, Revel D, Thivolet-Bejui F, Chalabreysse L, Maucourt-Boulch D, Jouneau S, Hachulla E, Cottin V
PRS19	ECONOMIC BURDEN OF RSV HOSPITALIZATION OF CHILDREN UNDER 5 YEARS OLD IN FRANCE BETWEEN 2010 AND 2018	Petrica N, Lemaitre M, Bardoulat I, Duret S, Watier L, Chosidow A, Lorrot M, Kieffer A, Demont C
PRS25	BUDGET IMPACT ANALYSIS OF THE CELL-BASED QUADRIVALENT INFLUENZA VACCINE IN THE GERMAN POPULATION USING A DYNAMIC TRANSMISSION MODEL APPROACH	Cai R, Schwehm M, Joaquin F. MQ
PRS40	ECONOMIC BURDEN OF ASTHMA AMONG ADULT PATIENTS IN THE URBAN POPULATION OF INDIA	Narang A, Goel R, Panchal M, Mittal R, Taneja L
PRS47	MANAGEMENT OF SEVERE ASTHMA IN PORTUGAL – INSIGHTS FROM A DELPHI PANEL	Arrobas A, Ferreira J, Lima R, Chaves-Loureiro C, Carreiro-Martins P, Mendes A, Pedrosa H, Faria M
PRS59	BASELINE CHARACTERISTICS AND REAL-WORLD TREATMENT PATTERNS OF NON-TUBERCULOUS MYCOBACTERIAL LUNG DISEASE PATIENTS IN COMMUNITY CARE SETTING GERMANY	Diel R, Obradovic M, van der Laan R, Siede J, Engelhard J, Kostev K
PRS80	THE CLINICAL PROFILE AND PRIMARY CARE PATHWAY FOR PATIENTS WITH SLEEP APNEA IN ITALY – A REAL-WORLD EVIDENCE RETROSPECTIVE COHORT STUDY	Viviani Anselmi C, Peduto I, Heiman F, Tettamanti A, Bajorek A, Iaru CM
CODE	SENSORY SYSTEM DISORDERS (PSS)	AUTHORS
PSS3	COST-EFFECTIVENESS ANALYSIS OF BIOLOGIC TREATMENTS FOR PLAQUE PSORIASIS IN ITALY – RESULTS OF THE CANOVA STUDY	Colombo D, Fiocchi M, Ori A, Simoni L, Bianchi L, Fabbrocini G, et al
CODE	SURGERY (PSU)	AUTHORS
PSU8	A COST ANALYSIS OF HEMOSTATIC SURGICAL RESOURCES ASSOCIATED WITH VERASEAL COMPARED TO STANDARD OF CARE IN ITALY	Mantuano M, Paragò V, Vrouchou P, Urbinati D
CODE	SYSTEMIC DISORDERS/CONDITIONS (PSY)	AUTHORS
PSY3	DISEASE MANAGEMENT OF PATIENTS WITH B-THALASSEMIA IN ITALY – CURRENT AND FUTURE PERSPECTIVES	Pinto L, Assanti M, Fiorentino F, Panetta C, Randon F
CODE	URINARY/KIDNEY DISORDERS (PUK)	AUTHORS
PUK25	ASSESSMENT OF ADHERENCE TO DRUG REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS – EVIDENCE FROM A SYSTEMATIC REVIEW	Ahlawat R, Goyal R

WINNER OF AN ISPOR GOLD CERTIFICATE OF RECOGNITION AS A TOP 10% POSTER



[Click here](#) for further details of poster abstracts available on the Virtual ISPOR 2020 website